trial

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCTId NCT02462473
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 9 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2016-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
9 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2015-05
Primary completion
2016-01
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
AripiprazoleOlanzapinePaliperidoneQuetiapineRisperidone

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Linked catalysts

1
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Pla — primary completion2016-01

Facts & assertions

4 sourced
Enrollment
9
Phase
PHASE2
Primary Completion Date
2016-01
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
Olanzapine
drug
Paliperidone
drug
Quetiapine
drug
Risperidone
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication